SCHEMBL5832552

SCHEMBL5832552

COc1cc(-c2nc3ccccc3o2)ccc1-c1ccc(N(C)C)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.59
PTGS2 P35354 1/20 0.47
MAPT P10636 7/20 0.46
RXFP1 Q9HBX9 2/20 0.46
TP53 P04637 2/20 0.45
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 4/20 0.44
TSHR P16473 3/20 0.44
HSD17B10 Q99714 3/20 0.44
USP2 O75604 2/20 0.44
HPSE Q9Y251 1/20 0.44
ALOX5 P09917 1/20 0.43
P2RY14 Q15391 1/20 0.42
HPGD P15428 3/20 0.42
CASP3 P42574 2/20 0.42
RAB9A P51151 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 1/20 0.42
HCRTR1 O43613 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832164 0.86 NPC1 (0.62) NPC1PTGS2MAPTRXFP1TP53
SCHEMBL5832587 0.85 NPC1 (0.61) NPC1PTGS2MAPTTP53KDM4E
SCHEMBL5832098 0.85 NPC1 (0.61) NPC1PTGS2MAPTTP53KDM4E
Hydrochloric Acid SCHEMBL5831703 0.81 NPC1 (0.65) NPC1PTGS2MAPTTP53KDM4E
SCHEMBL12956189 0.81 NPC1 (0.79) NPC1PTGS2MAPTTP53KDM4E
SCHEMBL5831907 0.79 NPC1 (0.65) NPC1PTGS2MAPTTP53KDM4E
SCHEMBL5832256 0.79 NPC1 (0.65) NPC1PTGS2MAPTTP53KDM4E
SCHEMBL5832513 0.79 NPC1 (0.53) NPC1PTGS2MAPTTP53KDM4E
SCHEMBL5832820 0.79 NPC1 (0.53) NPC1PTGS2MAPTTP53KDM4E
SCHEMBL5832825 0.78 NPC1 (0.64) NPC1PTGS2MAPTTP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885PTGS2 1019/4885MAPT 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.